CorMedix (CRMD) Expected to Announce Earnings on Tuesday

CorMedix (NASDAQ:CRMD) is projected to issue its quarterly earnings data before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of $0.05 per share and revenue of $27.46 million for the quarter.

CorMedix Stock Performance

NASDAQ:CRMD opened at $9.59 on Tuesday. The firm has a market cap of $581.89 million, a P/E ratio of -11.84 and a beta of 1.57. The firm has a 50-day simple moving average of $10.41 and a 200-day simple moving average of $9.40. CorMedix has a one year low of $3.03 and a one year high of $13.85.

Wall Street Analyst Weigh In

CRMD has been the subject of several recent analyst reports. StockNews.com upgraded shares of CorMedix to a “sell” rating in a research note on Friday, November 8th. D. Boral Capital reiterated a “buy” rating and set a $15.00 price objective on shares of CorMedix in a research note on Wednesday, January 22nd. Finally, Royal Bank of Canada boosted their price objective on shares of CorMedix from $11.00 to $12.00 and gave the stock an “outperform” rating in a research note on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, CorMedix currently has an average rating of “Moderate Buy” and an average target price of $15.67.

About CorMedix

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.